[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"local-recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:local-recurrence":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100618423","phase-2-mrg003-induction-and-capecitabine-maintenance-with-pd-1-in-locally-recurrent-npc-100618423",false,"NCT07331428","MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC","Efficacy and Safety of MRG003 With PD-1 Induction Followed by Capecitabine and PD-1 Maintenance as First-line Treatment in Locally Recurrent Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n\\*\\*Inclusion Criteria:\\*\\*\n\n1. Patients with locally recurrent nasopharyngeal carcinoma (NPC) more than 1 year after initial radical treatment for non-metastatic NPC, with or without regional recurrence, but without distant metastasis.\n2. Age 18-70 years.\n3. Pathologically confirmed local recurrence of NPC, staged as rT1-rT4 according to the 9th edition of the AJCC\u002FUICC classification.\n4. ECOG performance status score of 0-1.\n5. No prior radiotherapy, chemotherapy, immunotherapy, or biological therapy for recurrent NPC.\n6. No contraindications to immunotherapy or chemotherapy.\n7. Adequate organ function.\n\nExclusion Criteria:\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. Previous treatment with other PD-1 antibodies or immunotherapy targeting PD-1\u002FPD-L1 resulting in Grade III or higher immune-related adverse reactions.\n2. Residual toxic effects from prior anti-tumor treatments (including immunotherapy, targeted therapy, chemotherapy, or radiotherapy) (excluding alopecia, fatigue, and Grade 2 hypothyroidism) or clinically significant laboratory abnormalities higher than Grade 1 (CTCAE v5.0).\n3. Congenital or acquired immunodeficiency (e.g., HIV infection), active hepatitis B (HBV-DNA ≥10 copies\u002Fml), or hepatitis C (positive hepatitis C antibody and HCV-RNA above the detection limit of the assay).\n4. Known allergy to MRG003, capecitabine, or any component of anti-PD-1 antibodies.","ALL","18 Years","70 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg\u002Fkg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg\u002Fm², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.",[27,28],"Nasopharyngeal Carcinoma","Local Recurrence","NOT_YET_RECRUITING","2025-12-28",{"date":32,"type":33},"2026-01-09","ACTUAL",{"date":35,"type":21},"2026-01-01",{"date":37,"type":21},"2029-12-31",{"name":39,"class":40},"Fujian Cancer Hospital","OTHER_GOV",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100575924","phase-1-b7-h3-nir-imaging-for-osteosarcoma-surgery-100575924","NCT06778603","B7-H3 NIR Imaging for Osteosarcoma Surgery","Resection of Osteosarcoma in Limbs Navigated by B7H3-based NIR Lmaging: a Prospective, Single-center,Single-arm, Exploratory Trial","ROLN-B7-H3","Inclusion Criteria:\n\n* 1\\. Patients with histologically confirmed osteosarcoma of the limbs.\n* 2\\. the patients has not undergone tumor resection.\n* 3\\. Age between 18 and 60 years old.\n* 4\\. No prior systemic treatment for osteosarcoma.\n* 5\\. Measurable disease as assessed by imaging studies (e.g., MRI, CT).\n* 6\\. Adequate bone marrow, liver, and renal function.\n* 7\\. Written informed consent obtained from the patient.\n\nExclusion Criteria:\n\n* 1\\. History of other malignancies within the past 5 years.\n* 2\\. Pregnancy or lactation.\n* 3\\. Known hypersensitivity to any component of the B7H3-based NIR imaging agent.\n* 4\\. Uncontrolled intercurrent illness that would preclude safe study participation.\n* 5\\. Prior radiation therapy to the target lesion.\n* 6\\. Any medical condition that would compromise the patient's ability to undergo surgery or comply with study procedures.\n* 7.Patients not able to sign the Informed Consent.","60 Years",{"count":51,"type":21},32,[53,24],"PHASE1","Complete removal of all tumor tissue with a wide surgical margin is essential for the treatment of osteosarcoma (OS). However, it's difficult, sometimes impossible, to achieve due to the invisible small satellite lesions and blurry tumor boundaries. Besides, intraoperative frozen-section analysis of resection margins of OS is often restricted by the hard tissues around OS, which makes it impossible to know whether a negative margin is achieved. Herein, based on the high expression of B7-H3 in OS, a targeted probe B7H3-IRDye800CW is synthesized by conjugating anti-B7H3 antibody and IRDye800CW. This trial is aimed to investigate R0-resection rate and 2-y local recurrence rate after using this probe in Musculoskeletal tumor surgery for osteosarcoma as well as the safety parameters of this probe in human.",[56,57,58,28],"Osteosarcoma","Resection Margins","B7-H3 Probe",[60,61,62,63],"osteosarcoma","resection margins","B7-H3 Targeted Probe","local recurrence rate","RECRUITING","2025-01-11",{"date":67,"type":33},"2025-01-16",{"date":69,"type":33},"2024-01-01",{"date":71,"type":21},"2026-12-31",{"name":73,"class":74},"Peking University People's Hospital","OTHER",1]